1\. Voluntarily participate in the clinical study; fully understand and be informed about the study and sign the Informed Consent Form (ICF); willing to comply with and capable of completing all trial procedures.
2\. Diagnosed with DLBCL according to 2022 revised WHO lymphoma classification standards based on pathological diagnosis by the research center. For the dose-expansion phase, BCL-2 positivity (≥50% by IHC) is required.
3\. Age 18-70 years.
4\. No prior systemic anti-lymphoma therapy.
5\. Adequate organ and bone marrow function.
6\. At least one measurable or evaluable disease site according to the Lugano 2014 lymphoma efficacy evaluation criteria.
7\. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
You may not be if
1\. Lymphoma involvement in the central nervous system or meninges.
2\. Active infections.
3\. Uncontrolled clinical cardiac symptoms or diseases.
4\. Currently using (or unable to stop at least one week prior to the first dose) a known CYP3A strong inducer or strong inhibitor.
5\. Pregnant and lactating women, and subjects of childbearing age who do not want to use contraception.
6\. History of Human Immunodeficiency Virus (HIV) infection and/or Acquired Immunodeficiency Syndrome (AIDS).
7\. Patients with mental disorders or those unable to provide informed consent
Clareo Health | Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
